13/03/2020. Annual General Meeting Read more. Our data at the 2020 American Society of Hematology Annual Meeting is a demonstration of our ongoing dedication as we work to improve the lives of those impacted by hard-to-treat cancers, including blood cancers. Annual Report 2020. Astellas Submits New Drug Application for Enfortumab Vedotin in Japan. Thank you for visiting the Astellas Pharma Inc. Website. Full Annual Report 2019. Investors. March 2019, we have started publishing the Annual Report on our website. Global Immunogenetics Market Overview and Forecast Report 2020-2027– Top players:Pfizer Inc., Novartis AG, Astellas Pharma Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., UCB S.A Data Bridge Market Research analyses the market to grow at a CAGR of 6.9% in the above-mentioned forecast period MOST POPULAR . Full Annual Report 2020. The information in the online version "Annual Report" will be updated to the latest information as needed. Philips Annual Report 2020, the interactive summary version of the Philips financial- and sustainability Annual Report over the year 2020 including downloads in PDF format. Annual Report 2017. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nov. 05, 2019. The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. Focus Area Approach. The new acetylene plant at the Verbund site in Ludwigshafen, Germany, was gradually started up over a period of several months and has been in operation since 2020. Digital version; 2019 Prudential Relevance Report - Basel Accord Pillar III. For details, please refer to the full Legal Disclaimer. Sustainability Data Book. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Annual Report 2019. The information in the online version "Annual Report" will be updated to the latest information as needed. Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. Sanofi on Twitter. Sustainability Bond. Annual Report on Form 20-F 2016; Registration document 2016 (in French) Half-year financial report 2016; CSR publications. 13/03/2020. Letter to shareholders December 2020. The BMW Group Report 2020 will be published here on 17 March 2021 at 09.00 am CET. Annual Report 2020 PDF Please refer to the Consolidated Financial Statements for financial information. Download the Annual Review: High resolution: English (PDF 7.0 MB) | Deutsch (PDF 7.0 MB) Low resolution: English (PDF 2.0 MB) | Deutsch (PDF 2.0 MB) The report content encompases information found across the web pages of bunge.com, in Letter to shareholders August 2020. Annual Report 2020 is now available at the following link: https://www.astellas.com/en/investors/annual-report In order to provide timely information, we publish the Annual Report on the web site. The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2020. BBVA in 2018. NORTHBROOK, Ill., Aug. 4, 2020 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the call for entries for the Astellas Oncology C 3 Prize (Changing Cancer Care), a global challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones. Read More. The report meets GRI Standards - Core option, and satisfies basic components of SASB Standards. Download. Areas of Interest; Why Partner with Astellas; Primary Focus. Each forward-looking statement speaks only as of the date the last financial report. Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals. Reports Library; Build a report; WeCare; Hydrogen power; Crop nutrients; Investor presentations; Regulatory news; Investor calendar. Download our full Annual Report and Form 20-F Information for 2018. Astellas Biomedical Innovation Hub; Rx+® Data, Informatics and Analytics; Major Pipeline; Clinical Trials; Recommended. 19/02/2021. You are now leaving Astellas.us. This site includes information regarding products sold by Astellas in certain countries in the world. 13/03/2020. 17, 2020. However, some of those products are not approved by the regulatory authorities of other countries. Operating and Financial Review and Prospects,” together with the View the interactive digital version. Every day, Astellas is committed to making a difference for patients. Financial Summary. External. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Astellas Pharma Inc. has adopted International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2014. https://www.astellas.com/en/investors/annual-re... (English) https://www.astellas.com/jp/ja/investors/annual... (Japanese) Format Annual Report 2020 is now available. Astellas_AR2020_EN.pdf (English) Astellas_AR2020_JP.pdf (Japanese) Links. Download. Annual Report 2019 (PDF: 11MB / 48 pp.) - Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 - TOKYO and BOTHELL, Wash. – Feb. 18, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food... Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV. Annual Report 2020. Annual Report 2020. Astellas at ASH Annual Meeting 2020 Every day, Astellas is committed to making a difference for patients. Investors Library Top. 15/03/2019 . This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Published. Download our full Annual Report and Form 20-F Information for 2019. Sorry, you need to enable JavaScript to visit this website. The BMW Group Report 2020 is a new chapter in the reporting of the BMW Group. Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy . “Item 5. SEC Filings. 2020/12/09 Time period. RELATED CONTENT. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Investors. Copyright © 2018 Astellas Pharma US, Inc. California Declaration of Comprehensive Compliance Program, Vermont’s Pharmaceutical Marketer Price Disclosure, 2015 Biopharma Innovation Challenges and Solutions, Expanded Access to Investigational Medicines. Download PDF; Annual Report. Unfortunately, we weren't able to find a match. The website you are linking to is neither owned nor controlled by Astellas. IR Contacts Read more. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Annual Report 2020 report.adidas-group.com. Astellas Pharma annual/quarterly revenue history and growth rate from 2012 to 2020. Archives. - Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy - - EV-301 Intended to Support Global Registrations, Convert Accelerated to Regular Approval in U.S. - - Data Published in the New England Journal of Medicine, Presented at the 2021 ASCO Genitourinary Cancers Symposium - TOKYO and BOTHELL, Wash. – February 12... Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth. Figures up to fiscal year ended March 31, 2014, are based on Japanese generally accepted accounting principles (J-GAAP). Welcome - BASF Online Report 2020. Download PDF; Digital report; BBVA in 2019. TOKYO, February 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) – i.e., hot flashes associated... Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV. Mar. Astellas participates in Access Accelerated. April 2019 – March 2020 Files. Astellas Pharma Inc. 2016 Integrated Report; Chapter 4 of the Registration document 2016 (Grenelle II French law) Conflict minerals disclosure dated May 18, 2016; 2015 Financial reports. Annual Report 2020 for Communication on Progress Participant. All shareholder publications. TOYOTA Report. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Astellas Pharma’s Smyraf (ingredient: peficitinib) obtained regulatory approval for the treatment of rheumatoid arthritis, the third oral Janus kinase (JAK) inhibitor to receive approval. Feature Stories showcase the people and programs that bring to life the Astellas Way values and culture. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. 21, 2018. Financial Results. Enfortumab vedotin to be reviewed by Ministry of Health, Labour and Welfare for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health... Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives, Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women. Annual Results 2020; Key Financial Information; Quarterly production reports; Annual reporting. Annual Report 2019. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. Download PDF; Excel Annexes; Excel Tables; Digital report; Annual Report. Toyota Launches New Model Harrier in Japan. Letter to shareholders April 2020. Popular. Our heartfelt sympathy goes out to the people who have been affected by COVID-19. The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases. Investors. consolidated financial statements responsive to Item 18 of this Annual Report on Form 20-F (Annual Report) are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). Your browser does not support the video tag. Astellas Pharma Inc. has adopted International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2014. Please try again. Amidst the unprecedented public health challenge posed by COVID-19, we are focused on being a responsible and active partner in the communities where we work and live, as well as protecting the safety and well-being of our employees. Annual Report 2018. This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any products. CORPORATE GOVERNANCE REPORT Astellas Pharma Inc. 1 Date of last revision: June 30, 2020 Astellas Pharma Inc. Kenji Yasukawa Representative Director, President and CEO 1 Japanese yen equals 0.00881 U.S. dollars or 0.00778 euros as of December 2018. 1 Japanese yen equals 0.0095 U.S. dollars or 0.0081 euros as of October 2020. To enable deeper stakeholder understanding of Astellas' efforts to continue to create value for sustainable growth, we have published the annual report as an integrated report.In order to provide timely information, from FY2019, we have started publishing the Annual Report here on this website. The company is integrating its Annual Report and its Sustainable Value Report into one single report for the first time. Sorry, you need to enable JavaScript to visit this website. Financial Calendar Read more. This report is a copy of the online version "Annual Report" made on October 9, 2020 to improve corporate transparency by providing regularly recorded information. The information in the... Medical Care & Pharmaceutical Information, Rx+® - New Healthcare Solutions Beyond Medicine, Patient Outcome Maximization via Precise Surgery/Diagnosis, Research Activities on Tuberculosis and Malaria, Development of Pediatric Formulation for Schistosomiasis, Communication with the World Anti-Doping Agency (WADA), Five Fields of CSR-Based Management Diagram, Basic policy for procurement activities involving suppliers, Priority Areas of Astellas Domestic Social Contribution Activities, Astellas Environment, Health & Safety Guidelines, Biodiversity and Astellas An Enlarged Version, The Biodiversity Burden Index and Revenue, Environmental Impact of Products and Countermeasures, Environment-related Investments and Expenses, Providing Opportunities for Employees to Succeed Globally, Consolidated Financial Statements and Footnotes, Contributions to the Sustainable Development Goals, Structured to Promote Ethics and Compliance, Helpline for Employees and Encouraging a Speak-Up Culture, Astellas Anti-Bribery and Anti-Corruption Program, Group-Wide Volunteer Activities for Changing Tomorrow Day. Figures up to fiscal year ended March 31, 2014, are based on Japanese generally accepted accounting principles (J-GAAP). Full Annual Report 2018 . Annual Report on Form 20-F 2015 Financial reports. 2020-01-08: Annual Report 2019 for Communication on Progress: Active: 18-Sep-2019: Grace Letter: N/A: 2018-10-12: Communication on Progress: Active: 2017-10-13: Annual Report 2017 for Communication on Progress Details: Active: 2016-10-14: Annual Report 2016 for Communication on Progress: Active: 2015-10-15: Communication on Progress: Active: 2014-10-15: Astellas Annual Report 2014 This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth. Our 2020 Global Sustainability Report provides an overview of our performance and key activities from 2019 into the first half of the current year. PDF 11,262KB View online summary. Important Notice. Toyota Launches the New "Raize" in Japan. Corporate Governance Reports. Annual Report. PDF 7,964KB View online summary. Chairman of the Advisory Board (from 01.01.2020) Chairman of the Supervisory Board Münchener Rückversicherungs-Gesellschaft AG Dr. Andreas Kreimeyer Former member of the Board of Executive Directors and Research Executive Director BASF SE Dr. Frank Mastiaux (from 01.01.2020) Chief Executive Officer (CEO) EnBW Energie Baden-Württemberg AG Unfortunately, we weren't able to find a match for your search query. Download. Additional factors that may affect future results are contained in Vestas’ annual report for the year ended 31 December 2018 and these factors also should be considered. Annual Report. PDF 12,602KB View online summary. Follow us. In today’s fast-paced environment of healthcare and during this global pandemic, we remain focused on turning innovative science into solutions for patients. Partnering. To learn more about Astellas’ response to COVID-19, click, To learn more about updates to how we are helping to address evolving patient needs during COVID-19, click. Important Notice. TOKYO and SAN FRANCISCO, May 21, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas… Jun. In today’s fast-paced environment of healthcare and during this global pandemic, we remain focused on turning innovative science into solutions for patients. Dashboard 2020 report.adidas-group.com. This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any... Astellas participates in Access Accelerated.